MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9800
-0.0100 (-0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9900
Open2.0200
Bid1.9600 x 1400
Ask2.0500 x 800
Day's Range1.9000 - 2.0499
52 Week Range1.6200 - 42.7000
Volume177,670
Avg. Volume411,526
Market Cap23.324M
Beta (3Y Monthly)3.51
PE Ratio (TTM)N/A
EPS (TTM)-14.7390
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.75
Trade prices are not sourced from all markets
  • Those Who Purchased Melinta Therapeutics (NASDAQ:MLNT) Shares A Year Ago Have A 96% Loss To Show For It
    Simply Wall St.5 days ago

    Those Who Purchased Melinta Therapeutics (NASDAQ:MLNT) Shares A Year Ago Have A 96% Loss To Show For It

    As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...

  • PR Newswire12 days ago

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates
    Zackslast month

    Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Melinta Therapeutics, Inc.: 1Q Earnings Snapshot

    On a per-share basis, the New Haven, Connecticut-based company said it had a loss of $2.34. The drugmaker posted revenue of $14.1 million in the period. In the final minutes of trading on Thursday, the ...

  • GlobeNewswirelast month

    Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    ~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million,.

  • GlobeNewswirelast month

    Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including results from its real-world registry studies of VABOMERE® (meropenem and vaborbactam), ORBACTIV® (oritavancin), and MINOCIN® (minocycline) for Injection at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting held from May 8-11 2019 in Orlando, Florida. "Our presentations demonstrate Melinta’s continued commitment to combatting antimicrobial resistance by helping to inform clinical decision-making for the responsible and sustainable use of our antibiotics,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 financial results on May 9, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Thursday, May 9, 2019, at 4:30 p.m. ET to discuss its financial results and provide a business update. On May 9, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #5233509.

  • PR Newswire2 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire2 months ago

    Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands. “The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta.

  • GuruFocus.com3 months ago

    Melinta Therapeutics Inc (MLNT) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Melinta Therapeutics Inc (NASDAQ:MLNT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire3 months ago

    Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

    ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018,.

  • GlobeNewswire3 months ago

    Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to discuss its financial results and provide a business update. On March 13, 2019 at 4:30 p.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID #1698998.

  • TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
    Zacks4 months ago

    TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%

    TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • GlobeNewswire4 months ago

    Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding

    MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) --  Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the initial $75 million disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. In addition, the previously announced amendment to the facility agreement with funds managed by Deerfield Management Company, L.P. (collectively, “Deerfield”) also became effective.

  • GlobeNewswire4 months ago

    Melinta Therapeutics Announces One-for-Five Reverse Stock Split

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a one-for-five reverse stock split of the Company's common stock, par value $0.001. The reverse stock split, which was approved by the Company's stockholders at a special meeting held on February 19, 2019, will be effective at 5:00 pm Eastern Time today.

  • GlobeNewswire4 months ago

    Melinta Therapeutics Provides Corporate Updates

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today provided an update on its strategic repositioning initiatives, cost savings outlook, as well as new management appointments. The Company continues to execute on its strategic initiatives aimed at repositioning the business to drive profitable growth and value creation. “We have been moving with purpose and focus over the past several months to reposition Melinta and set a new trajectory towards growth and value creation,” said John H. Johnson, interim chief executive officer and director of Melinta Therapeutics.

  • PR Newswire5 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
    Zacks6 months ago

    Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%

    Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire6 months ago

    John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive officer (CEO) of Melinta, subject to the terms of an employment contract and the close of the previously announced commitment for a credit facility of up to $135 million from Vatera Healthcare Partners LLC. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22, 2018. “John is a biopharmaceutical industry leader with a proven track record of growing businesses and unlocking value, and we are confident that he is the right person to lead Melinta into its next phase of growth and development,” said Kevin T. Ferro, chairman of Melinta Therapeutics.

  • GlobeNewswire6 months ago

    Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million

    “We believe that, following negotiations and the expected close of a definitive agreement, this new credit facility from Vatera will take us to approaching cash flow breakeven as we continue to position Melinta to achieve profitable growth and drive stockholder value creation,” said John H. Johnson, interim chief executive officer and director of Melinta. “Since I became interim CEO, we have undertaken a number of operational improvements to lower costs and strengthen the business, and we are seeing the results of those efforts reflected in our accelerating sales momentum.

  • GlobeNewswire6 months ago

    Dova Pharmaceuticals Announces Management Changes

    Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter.

  • Zacks6 months ago

    Jazz (JAZZ) Increases Share Buyback Authorization by $400M

    Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.

  • GlobeNewswire7 months ago

    INVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders – MLNT

    RADNOR, Pa., Nov. 30, 2018 -- Kaskela Law LLC is investigating Melinta Therapeutics, Inc. (“Melinta” or the “Company”) (NASDAQ: MLNT) on behalf of stockholders.  The.

  • GlobeNewswire7 months ago

    Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the European Commission (EC) has approved Vabomere® (meropenem and vaborbactam) for use in adult patients with complicated intra-abdominal (cIAI) and urinary tract infections (cUTI), hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP), bacteraemia that occurs in association with any of these infections, and infections due to aerobic gram-negative organisms where treatment options are limited. Marketing authorization was granted in all 28 European Union (EU) member states, as well as Norway, Iceland and Liechtenstein.